P281 Body composition in adults with cystic fibrosis – are measurements taken using single frequency and multifrequency devices interchangeable? D. Proud 1 , L. Tan 2 , D. Lau 2 , R.I. Ketchell 2 , H. Jones 3 , M. Rezaie 2 , J. Duckers 2 . 1 Cardiff & Vale University Health Board, Llandough, United Kingdom; 2 Cardiff & Vale University Health Board, Cardiff, United Kingdom; 3 Cardiff University, Cardiff, United Kingdom Objectives: Nutritional status is known to affect pulmonary function and bioelectrical impedance assessment (BIA) has become increasingly popular as a tool to assess body composition and thus nutritional status. However, a number of variations of BIA devices are available utilising either single-frequency (SF) or multi-frequency (MF) technology. To date, it is not known how SF and MF BIA compare in adult patients with cystic fibrosis (CF). The aim of this study is to compare and evaluate SF and MF BIA technology in adult patients with CF. Methods: SF and MF BIA were performed on the same patient on the same day when attending their annual review. SF BIA was performed using a Tanita bc418ma whilst MF BIAwas performed using a Bodystat Quadscan 4000 device. BIA results compared included estimated total body water calculated as a percentage of total weight (TBW%), fat mass (FM) and fat free mass (FFM) both measured in kilograms (kg). Results: 112 patients (43 female), 93 (83%) pancreatic insufficient, mean age 30.3 years (range 17–59), mean forced expiration in 1 second (FEV 1 ) 73% predicted (range 12–133) underwent both SF and MF BIA. TBW%, FM and FFM measurements were significantly different when measured using SF and MF (TBW% p < 0.01, FM p < 0.001, FFM p < 0.001). Conclusion: BIA technology can be informative regarding body compos- ition changes over time in an individual. However, SF and MF BIA data may not be interchangeable therefore caution must be applied when interpret- ing different BIA data. With suitably developed conversion equations it may be possible to compare different BIA results thus improving the potential to utilise BIA technology in multicentre studies regardless of device used. P283 Results of a change in vitamin supplementation for cystic fibrosis patients in a tertiary paediatric centre A.A.M. Hafiz 1 , A. Forster 1 , E. Turner 1 , E. Sheppard 1 , S. Wilkinson 1 , A. Maitra 1 , A. Shawcross 1 . 1 Royal Manchester Children’s Hospital, Manchester, United Kingdom Background: Children with cystic fibrosis (CF) who are pancreatic insufficient (PI) require supplementation of fat-soluble vitamins. Previously, this required multiple supplements which increases the burden of medication, and dosing appropriately can be challenging. Royal Manchester Children’s Hospital (RMCH), a large tertiary paediatric CF centre in Northwest England, switched to Paravit-CF due to cheaper costs, easier dosing consistent with recommendations and reduced medication burden. Objective: We aimed to compare patients’ results for blood vitamin levels of vitamins A, D and E to ensure levels remained therapeutic after the switch to Paravit-CF. Methods: All PI patients under our centre were identified. Medical records were reviewed to determine the patients’ dose and preparations of vitamin supplementation prior to the switch, and Paravit-CF dose afterwards. Vitamin levels at the annual review appointment prior to the switch and 3– 6 months after switching were compared. Results: 138 patients will be included in final analysis (mean age 8.45 y, 55% male). Data from 75 patients has been analysed to date with the remaining due by February 2020. 57% of patients switched from standard dosing of multiple vitamin supplements to a standard dose of Paravit-CF with vitamin levels remaining normal both pre-and post-change. Of those patients requiring a higher than standard dose of vitamins A&D prior to the switch, or with low levels of vitamin A or D on a standard dose, 92% now have normal levels on a standard dose of Paravit-CF. However a total of 13/ 75 (17%) of patientsto date show low levels of vitamin E on Paravit-CF. Conclusions: Paravit-CF is well-tolerated and the majority of patients demonstrate unchanged or improved vitamin levels compared to their previous preparations. This is achieved at a reduced cost, with a reduced burden of care. Further consideration is required for those patients with low levels, particularlyof vitamin E, on Paravit-CF. P284 The impact of eating habits in different geographic regions on the body mass index of Croatian cystic fibrosis patients A. Vukic Dugac 1,2 , A. Ladic 3 , I.K. Crnogorac 4 , A. Dobric 4 , L.T. Dobric 4 , L. Tanackovic 4 , I. Bambir 5 , I. Lalic 1 , T. Odobasic Palkovic 1 , D. Tjesic-Drinkovic 4,5 , D. Tjesic-Drinkovic 4,5 . 1 University Hospital Centre Zagreb, Clinic for Respiratory Disorders ‘Jordanovac’, Zagreb, Croatia; 2 University Hospital Centre Zagreb, School of Medicine, Zagreb, Croatia; 3 University Hospital Centre Zagreb, Department of Gastroenterology, Zagreb, Croatia; 4 University of Zagreb, School of Medicine, Zagreb, Croatia; 5 University Hospital Centre Zagreb, Department of Pediatrics, Zagreb, Croatia Eating a balanced diet is essential for people with cystic fibrosis. Maintaining a good nutritional status can help a person improve their well-being, keep their symptoms under control, and fight infections. The results of our study also suggest that when it comes to the nutritional status of CF patients, we have to consider the eating habits of different regions in country. Objectives: Most patients with cystic fibrosis (CF) require a higher energy and protein intake than their healthy peer group. There are few data on dietary intakes of adult patients. The aim of this study was to determine the difference in BMI among Croatian CF patients, depending on the differences in eating habits in various regions of the country. Methods: Data for this study were derived from paediatric and adult sources. Patients’ medical records were evaluated and analysed using R: A language and environment for statistical computing (2015). BMI was calculated from measured weight and height. Croatia was divided into 5 different geographical regions, according to climatic conditions and eating habits. A one-way between subjects ANOVAwas conducted to compare the effect of a specific region on a BMI, with a significance set at p < 0.05. Results: Fifty-three paediatric (25F, 28M) and 38 adult (20F, 18M) CF patients were included in the study. Mean age and BMI of paediatric cohort were 11.6 years and 17.22 kg/m 2 respectively, while in adult cohort mean age and BMI were 24.9 years and 21.2kg/m 2 . There was no statistically significant difference in BMI across different Croatian regions for paediatric population (F (4,48) = 2.43, p = 0.06), contrary to adult population ((F3,34) = 3.34, p = 0.03). Post hoc comparisons, using the Tukey HSD test, indicated that the significant difference existed between central and mountainous Croatian region (p = 0.02). P285 Lower residual fat malabsorption and improved growth in children with cystic fibrosis treated with a novel oral lipid technology supplement V. Stallings 1,2 , A. Tindall 1 , A. Maqbool 1,2 , M. Mascarenhas 1,2 , J. Schall 1 . 1 Children’s Hospital of Philadelphia, Div. of Gastroenterology, Hepatologyand Nutrition, Philadelphia, United States; 2 University of Pennsylvania, Perelman School of Medicine, Philadelphia, United States Objectives: Malabsorption and optimizing growth/nutritional status in patients with cystic fibrosis (CF) and pancreatic insufficiency (PI) is a challenge. A highly absorbable lipid (LYM-X-SORB™, now Encala™, Envara Health Inc, Wayne, PA) improved fat absorption, growth, choline and essential fatty acid (EFA) status in a 12-month double-blind randomised placebo-controlled trial. Coefficient of fat absorption (CFA) increased by 6% over 12 months with Encala. This secondary analysis is to determine Encala effectiveness in subjects with varying CFA. Methods: This analysis was restricted to subjects with baseline CFA and a 3-month visit (n = 66, 10.5 ± 3 yrs, 40% female). Encala and placebo/ comparator (COMP) had similar calorie (303–456 kcal/d) and fat (11– 18g/d). CFA was from 72-hour stool and weighed food records. Subjects Posters / Journal of Cystic Fibrosis 19S2 (2020) S55–S168 S135